Title:
CHIDAMIDE-CONTAINING ANTI-TUMOR PHARMACEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/027912
Kind Code:
A1
Abstract:
Disclosed are a chidamide-containing anti-tumor pharmaceutical composition and the use thereof. Provided is a chidamide-containing anti-tumor pharmaceutical composition, comprising chidamide and a cellular-mesenchymal epithelial transition factor (c-Met) inhibitor, or chidamide and an anaplastic lymphoma kinase (ALK) inhibitor, or chidamide and an inhibitor of repressor of silencing 1 (ROS1).
Inventors:
ZHOU YOU (CN)
XIN LIJUN (CN)
PAN DESI (CN)
SHAN SONG (CN)
NING ZHIQIANG (CN)
XIN LIJUN (CN)
PAN DESI (CN)
SHAN SONG (CN)
NING ZHIQIANG (CN)
Application Number:
PCT/CN2020/109102
Publication Date:
February 18, 2021
Filing Date:
August 14, 2020
Export Citation:
Assignee:
SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN)
International Classes:
A61K45/06; A61K31/4406; A61P35/00
Foreign References:
| CN101837129A | 2010-09-22 | |||
| KR20180120565A | 2018-11-06 | |||
| CN101653608A | 2010-02-24 | |||
| CN110833544A | 2020-02-25 |
Other References:
ZHANG, N.N. ET AL.: "Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC.", JOURNAL OF CANCER., vol. 10, no. 5, 29 January 2019 (2019-01-29), pages 1275 - 1287, XP055779772
LUAN, Y.P. ET AL.: "Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 62, no. 7, 12 November 2018 (2018-11-12), pages 3171 - 3183, XP055779773
LUAN, Y.P. ET AL.: "Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 62, no. 7, 12 November 2018 (2018-11-12), pages 3171 - 3183, XP055779773
Attorney, Agent or Firm:
CHINA PATENT AGENT (HK) LTD. (CN)
Download PDF: